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Abstract 
Advances in anticancer therapies and increasing attention towards patient quality of life make 
Supportive Care in Cancer (SCC) a key aspect of excellence in oncological care. SCC promotes a 
holistic conception of quality of life encompassing clinical, ethical/existential, and spiritual 
dimensions. Despite the calls of international oncology societies empirical evidence shows that SCC 
has not yet been implemented. More efforts are needed given the clinical and ethical value of SCC 
not only for patients, but also for clinicians and hospitals.  
Drawing on different literature sources, we identify and discuss three important barriers to the 
implementation of SCC: 1) organisational - lack of adequate resources and infrastructures in over-
stretched clinical environments, 2) professional- burnout of cancer clinicians; and 3) cultural - stigma 
towards death and dying.  
We add an ethical counselling framework to the SCC implementation toolkit- which, could offer a 
flexible and resource-light way of embedding SCC, addressing these barriers.   
Keywords: Cancer; Supportive Care; Ethical Counselling; Palliative Care; Implementation; Illness 
trajectory  
1. Introduction  
Medical advances in oncology have led to an increase in cancer survival rates; more patients 
are cured or live longer with cancer. However, not only cancer treatments, but also 
receiving a diagnosis [1], can have major health and psychosocial impact for patients. 
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Therefore addressing the clinical and psychosocial dimensions of cancer in a timely manner 
can improve the quality of life of patients and increase survival rates [2]. This is why 
supportive care in cancer (SCC) is increasingly seen as a key aspect of the excellence of 
oncological care.  
Despite the clinical and ethical value of SCC, and the high level of consensus about the need 
to integrate it in standard oncological practice [2-4], the implementation of SCC still has a 
long way to go world-wide. Most services still consider SCC a resource to be used after 
curative care [5, 6]. When available, SCC services are often accessed by chance, and are 
often not integrated with oncological practice [7, 8].  
The implementation of evidences coming from biomedical research is a widely investigated 
and very challenging phenomenon [9] – in oncology, as in other medical specialities. 
Interestingly, the model of supportive care we are discussing was first developed almost 10 
years ago in geriatric medicine [6], therefore SCC is not even an entirely new care paradigm 
in medicine. 
In this paper we bring together different literature sources to identify and discuss barriers to 
the implementation of SCC. We searched the literature on SCC, implementation, clinical staff 
wellbeing, biomedical humanities intended in a wide sense [10] in three databases PubMed, 
Web of Science, and Google Scholar. In our search strategy we searched for publications with 
the key terms in the title and/or abstract including: ‘supportive care’, ‘palliative care’, ‘end of 
life care’, ‘cancer trajectory’, ‘patient and family centred care’, ‘participatory oncology’, 
‘intervention’, ‘implementation’. Inclusion criteria for articles were English-language 
commentaries, reviews, papers. We also searched relevant journals separately, as well as the 
references of our initial finds, to ensure we had not omitted any relevant literature. 
The analysis of the literature allowed us to identify three key barriers to the implementation 
of SCC: 1) resource and organisational - lack of adequate resources and infrastructures, 2) 
professional- physician and health care provider burnout, and 3) cultural - stigma towards 
death and dying.  
We further contribute to the body of literature analysed by adding to the SCC 
implementation toolkit an ethical counselling and medical decision-making framework 
developed by Boniolo et al [11]. We suggest that while being not too resource-intensive, this 
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framework could help to embed SCC in the current oncological practice, addressing the 
above-mentioned barriers.   
1.1 What is Supportive Care in Cancer and what are the problems it raises? 
 
There is not a precise definition of SCC. This is probably because SCC includes – and is 
sometimes also conflated with – palliative care, end of life care (also referred to as ‘hospice 
care’), and other terms such as ‘early palliative care’, or ‘early palliative and supportive care’ 
[12, 13]. Table 1 provides a terminological clarification of the different meanings/aspects 
attributed to SCC; this is complemented by Figure 1 which shows a conceptual framework 
for SCC, palliative and hospice care (taken from [14]). 
 
Table 1 Terminological clarification  
Supportive care 
in cancer /early 
palliative and 
supportive care 
Prevention and management of the adverse effects of cancer and its treatment at all 
stages of the illness. It includes three main aspects: control of complications of cancer 
and/or its therapy; the management of pain, chronic complications and psychosocial 
support once oncological therapy is no longer curative (see palliative care); and the 
approach of the end of life 
Palliative care  
 
An approach that improves the quality of life of patients and their families who are 
facing problems associated with life-threatening illness, when cure is unlikely or not 
possible.  It offers a support system to help patients live as actively as possible until 
death. So palliative care is a measure that helps but does not cure patient from disease. 
End of life/ 
hospice care  
Palliative care when death is imminent 
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Figure 1 Conceptual framework for SCC, palliative and hospice care (taken from [14]). Under 
this framework, hospice care is an arm of palliative care which, in turns is an arm of 
supportive care.   
 
 
Acknowledging the abovementioned semantic difficulties, it is possible to identify some core 
tents of SCC. SCC deals with clinical and psychosocial needs of cancer patients in order to 
provide optimal quality of life [13]. SCC includes control of acute complications of cancer 
and/or its therapy; the management of pain, chronic complications and psychosocial 
support once oncological therapy is no longer curative; and the approach of the end of life. 
Therefore, SCC can address all stages of cancer: curative, palliative and terminal treatment 
[15].  
The integration of SCC within the illness trajectory can be used by clinicians to conceptualise 
SCC within patients’ care (although, as mentioned above, this concept is taken from 
geriatrics). Notably, it shows how elements of supportive care can start very early in the 
cancer trajectory – and that, ideally, care should not stop with the death of the patient but 
may involve bereavement care for their family/caregivers. 
 
SCC has a strong ethical value, as it considers patients’ needs holistically. It goes beyond the 
biomedical dimension of cancer to encompass the ethical/existential and psychosocial 
dimension of illness, thus honouring the important clinical principle of patient centeredness. 
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Moreover, SCC is also underpinned by a professional and ethical obligation of honesty and 
transparency towards patients receiving a diagnosis or starting any treatment, to provide 
them (if they so wish) with comprehensive information about the clinical and care pathways 
available. SCC includes preparing the patient with non-curable cancer for the reality of 
available treatment possibilities, avoiding over treatment which may interfere with the 
preservation of an optimal wellbeing. Thus, SCC promotes more realistic and professionally 
meaningful dialogues with patients. 
While realistic expectations about prognosis are important, the patient-centeredness of SCC 
implies that the level and amount of such information should be flexible to what patients 
and family want and need to know, bearing in mind their potentially high vulnerability. 
Therefore, SCC communication involves many clinical and ethical issues, and requires 
qualified providers with special expertise.  
The ethical value of SCC extends beyond the patient. SCC can also empower family members 
or other caregivers and can help clinicians to plan care in advance. Moreover, a well-
implemented SCC may reduce hospital admissions, and may encourage fruitful 
collaborations between oncology and other medical specialties.   
International efforts have been made by medical societies to provide specific guidance on 
the implementation of SCC or some aspects of SCC within the patient trajectory [2, 3, 16]. 
The importance of SCC is further testified by the fact that it addresses most of the targets 
identified by the World Cancer Declaration to achieved by 2020 [17]. These include: 
availability of cancer-control plans in all countries; dispelling misconceptions about cancer; 
diagnosis and access to cancer treatment, including palliative care, improved worldwide; 
universally available effective pain control; greatly improved training opportunities in 
oncology; major improvement in cancer survival in all countries.  
Based on the available evidence, the key features and benefits of SCC are summarized in 
Table 2.  
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Table 2 Key features and benefits of SCC   
Key Feature of SCC Benefits & Evidence  
Timeliness 
SCC should be integrated 
with the illness trajectory 
from cancer diagnosis and 
throughout the 
continuum of disease   
(including end of life and 
survivorship care).  
 
The time of diagnosis is often also a very stressful time when patients can be 
vulnerable [18]. Patients tend to become informed and confident in their input 
into the decisions affecting them as the cancer trajectory unfolds. However 
the time of diagnosis is already a point in which key decisions are required and 
most medical and psychosocial issues of survivorship or end of life care begin 
[19]. It is important to highlight that patients who have early access to 
palliative approaches (an aspect of SCC) -whether their cancer is advanced or 
not- have better quality of life; reduction in hospital admissions and in 
aggressive cancer treatments at the end of life (and more home or hospice 
deaths)[20]; and live longer than those who receive standard care [18].   
Patient centeredness 
Clinicians should involve 
patients (and family/care 
givers) in the decision-
making process to address 
individual preferences, 
respecting their wishes 
and vulnerability.  SCC 
should be flexible to the 
patient, and patient (or 
guardian) consent should 
be required. 
Patient centeredness is an important tenet not only of SCC and oncology [21], 
but also of healthcare in general.  
Patient centered approaches promote patient’ feeling of self-efficacy which in 
turn lead to more favourable outcomes [22], fewer hospitalisation and 
increased survival rate [23]. Subjective theories of illness should also be 
considered as they may provide an opportunity to recognise patient need for 
support [24].  
There can be significant conflicts between patient and family (and care givers) 
regarding treatment decisions [25]. Functional interactions among families, 
patients, and clinicians are essential to promote good decisions and quality of 
life. In case of conflicting views about therapy with patients (and their 
family/caregivers), clinicians should be able to achieve a common therapeutic 
goal [26] with the patients. Both patients and family members can benefit 
from various forms of psychological intervention. Therapeutic goals need to be 
reviewed regularly as patients’ preferences/needs can change.  
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Multispecialty  
SCC requires 
multidisciplinary teams 
(MDT) of medical and 
non-medical professionals 
that can care for a variety 
of physical, psychological, 
social and 
ethical/existential needs 
of patients.  The tasks and 
responsibilities of these 
MDT should vary around 
the needs of patients. 
However, the oncologist 
who normally execute the 
diagnosis and is in charge 
of treatment and care 
should act as a 
coordinator.   
The medical and psychosocial aspects that SCC could cover can be incredibly 
complex and variable, as is cancer. They can encompass: the management of 
therapy heterogeneity [27] and polypharmacy  (e.g. interaction of 
antidepressants with anticancer agents[28]), oncofertility [29], end of life care 
for children and adolescents [30], art interventions to alleviate the 
chemotherapy related distress [31].  It should also be stressed that 
complications can continue to occur 20 to 30 years after treatment – this 
requires prolonged follow-up which are necessarily associated to psychological 
stress [13]. 
Disease trajectory parallels – e.g.  with non-malignant cardiorespiratory 
diseases [5] – make MDT and multi-speciality dialogue even more vital. MDT 
should be responsive to the different cultural background of patients (and 
family and /caregivers), and sensitive to the different health values and 
attitudes of each patient [32].  
Being open and responsive to patients’ culture and spirituality is an important 
feature of SCC [33]. Patients’ spiritual claims may also mask denial or 
unresolved conflicts, requiring patient referral for proper counselling.  
 
Training and Research 
More training and 
research are needed to 
help clinicians, MDT and 
patients navigate the 
difficult clinical ethical 
legal and psychosocial 
issues that SCC can 
present.   
SCC requires specific education and training that are not yet provided in most 
medical schools or at ongoing stages of career development. Clinicians 
involved with dying patients should consider their own preferences and views 
of a good death and recognise that these values may not be shared by the 
patient they are caring for [34].  Clinicians may also need to be trained in 
leadership/management and communication training to effectively work in 
MDT[2]. 
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2. Implementation challenges  
 
1) Organisational barriers: lack of adequate resources and infrastructures   
 
SCC often requires multidisciplinary teams (MDT) collaboration, and can be time and 
resource intensive. However, most health services worldwide are insufficiently funded and 
experience extraordinary pressure to work with limited resources [35].  It can therefore be 
very challenging to implement SCC in overworked healthcare systems, and there is a risk 
that SCC may be seen by clinicians as an additional unwelcome or unfeasible task. 
However, from a resource perspective, it is equally important to consider that aggressive 
cancer treatments can be very expensive [36]. Moreover, lack of appropriate 
communication between patient and clinicians, and the lack of adequate psychosocial 
services, may have a negative impact on patient ability to adapt and adjust to cancer, 
contributing to patient distress, leading to anger, and to an increased risk of litigation based 
on what could be called ethical malpractice [37]. 
Alongside thinking about resource implications, it is key to ensure that other organisational 
and infrastructural barriers to the implementation of SCC are removed.  
Qualitative research reported a mismatch between clinicians’ understanding of patient 
autonomy and centeredness and the reality of oncology clinical practice.  Whilst clinicians 
see patients’ preferences as central to decision-making, they also highlight how 
organisational factors such as competing clinical and administrative responsibilities, and 
structural limitations to care (e.g. barriers to obtaining approval for systemic therapies) may 
ultimately limit patient choice [38]. Compliance points, meeting targets, financial rewards 
can subvert oncologists’ professionalism, directly or indirectly impeding discussions about 
the possible dimension of care available to the patients beyond cancer treatment. Clinicians 
often have to justify why patients are not following  certain treatment pathways (prescribed 
by regulatory bodies), or they – or the hospital/service they work in – can receive financial 
rewards  based on the number of certain specific treatments prescribed [25].     
These few examples illustrate how the professional autonomy of clinicians is a paramount – 
but often backgrounded – aspect to the achievement of genuine patient autonomy and 
centeredness. Charlotte Williamson, the first chair of the UK Royal College of General 
Practitioners’ patient liaison group, vividly highlights how the realisation of patient 
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centeredness and autonomy requires autonomy also from healthcare professionals:  
“Patient autonomy requires that the patient be free of coercion, whether overt or covert. 
The doctor too must be free of coercion, free to explore values, perspectives, anxiety and 
clinical evidence, free to discuss all possible courses of action with the patient” [39].  This 
important observation is linked to ethical debates about the relational nature of autonomy – 
which recognise that individuals are immersed in a network of relations and 
interdependencies [40]. As already discussed in the delineation of the key features of SCC 
(see Table 2), such network includes clinicians, but also other actors such as family members 
and caregivers. Acknowledging the relationality of patient autonomy is vital to the 
successful implementation of patient centeredness in SCC (and in other clinical settings).  
2) Professional barriers: burnout of cancer professionals  
 
There are elevated rates of burnout among cancer professionals worldwide:  
a recent study suggest a prevalence of 35% in medical oncologists, 38% in radiation 
oncologists, and 28% to 36% in surgical oncologists [41] 1. Burnout can impact the quality of 
care received by patients, but it also has potentially profound implications for oncologists 
(and healthcare systems), including suicidal ideation, desire to retire early, and leaving the 
profession altogether. 
The burnout of oncologists, and of the clinical workforce in general, is a very complex and 
widespread problem which blends individual, organisational and cultural aspects [42]. The 
main reported factors associated to burnout in oncology specialists include: feeling of 
isolation and lack of time to connect with colleagues [43]; feeling unsupported after difficult 
deaths; difficulties conceptualizing a “good” versus “bad” death [44];  difficulties breaking 
bad news; difficulties offering end-of-life care and spiritual support; difficulties dealing with 
cross-cultural issues  and in dealing with patients’ families [45].  
Most of the suggested solutions comprise: communication training aimed at improving 
oncologists’ relationships with patients (and families/caregivers), and with MDT [46]; 
debriefs; and self-care and awareness plans for oncologists, particularly those who care for 
patients with life limiting cancer [47]. These solutions echo the aforementioned idea of 
                                                          
1 See also https://am.asco.org/professional-burnout-and-oncology-workforce-perspective-physician-assistants-
and-nurse-practitioners  
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relationality of patient autonomy in SCC (and care in general) – highlighting how it can be 
equally important for clinicians to be equipped with tools to deal with the clinical and 
emotional demands of delivering care for cancer patients. Interestingly, most of the causes 
of and suggested solutions to oncologists’ burnout are addressed by SCC.  The need for 
more research and training (to improve patient communication), the emphasis on the 
ethical value of caring for different aspect of patient quality of life (e.g. existential/spiritual), 
the value of introducing palliative care early in the illness trajectory, and the importance of 
MDT work are in fact key features of SCC. Therefore, alongside benefiting patients, 
adequate implementation of SCC may also help to address the issue of oncologists’ burnout.   
3) Cultural barriers: stigma towards death and dying  
 
To put it bluntly, adequate (therefore also timely) implementation of SCC ultimately entails 
discussing openly the possibility of – and when necessary thinking about and planning – 
death and dying, early in the cancer trajectory.  This core aspect of SCC is a much entangled 
implementation hurdle. Researchers from diverse disciplinary backgrounds have highlighted 
a tendency in our society to regard death as ‘a’ or ‘the’ great enemy and/or as a taboo. This 
tendency foregrounds the idea of cure, and deflects attention towards disease, suffering, 
and care – three pillars of SCC.  
In the past, dying at home with relatives was the norm, death was more integrated with life 
and it was made more tolerable by the social and religious environment [48]. Currently 
more than half of the deaths in industrialised counties occur in hospitals (often in Intensive 
Care Units). Death and dying have been made ‘invisible’ and ‘controlled’ through 
hospitalisation [49]. They tend to be treated as a medical problems or failure, rather than 
natural events [50]. This makes dying less socially personalised and may prolong and disrupt 
the bereavement process [13]. The consequent trauma can in turn feed the fear and stigma 
towards death.  
The difficulty in planning SCC and discussing prognostic uncertainty is often underpinned by 
such stigma [50].  Clinicians tend to view disclosing uncertainty as potentially damaging to 
the doctor-patient relationship and often give falsely optimistic prognosis to dying 
patients [25]. These ‘optimistic’ prognoses can lead patients to pursue intense – even 
experimental and potentially harmful [51] – treatments near the end of life, at the expense 
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of palliation. Oncologists have expressed concern that a referral to palliative care would 
destroy patient’s hope [52]. Cancer centres homepages rarely mention palliative care 
services, while webpages with palliative care content sometimes omit information about 
early use of care [53].  
Studies showed that patients attach a strong stigma to palliative care, even after a positive 
experience with early palliative intervention [54]. However, there seem to be no evidence 
that prognostic disclosure makes patients less hopeful. There is instead evidence that 
disclosure of prognosis can support hope, even when the prognosis is poor [55]. 
Moreover widespread metaphors of ‘war’ and ‘fight’ [56] are not only misleading but also 
dangerous, as the pressure to be ‘positive’ can hinder patients/families caregivers to talk 
about fears [57] and may ultimately obstruct decision making – biasing it towards aggressive 
treatments[25]. The media can also contribute to nurturing this cultural trope of ‘fight’ by 
offering often an over-optimistic view of the success of medical treatments [58]. 
More research on the impact of prognosis communication on patient outcomes is needed to 
improve prognostic discussion [59].  
Notably, studies have shown how the term ‘supportive care’ seems to be much better 
received by patients than other terms such as ‘palliative care’ [60]. Moreover there is 
evidence that addressing anxiety/fear towards death can reduce clinicians burnout and 
improve patient outcomes [61]. The idea of improved and more comprehensive 
communication about the risks and benefits of aggressive cancer therapy and of other 
options offered by SCC would more often discourage potentially harmful intensive 
treatment and encourage autonomous and meaningful choices. Referrals to palliative care 
and hospice services often occur much too late to provide substantial benefit, if the referrals 
occur at all [62].  
3. Supporting SCC 
More efforts need to be made to implement SCC, given the enormous benefits of SCC not 
only for patients, but potentially also for clinicians and hospitals. SCC can improve 
symptoms, reduce hospital costs, optimise the planning and coordination of care [63]. It can 
reduce inappropriate hospital admission[64], costs in healthcare systems [65],  burnout and 
retention of staff. 
12 
 
It is very challenging to suggest a detailed and unique model of the implementation of SCC 
given the cultural differences in patients’ and families’ health beliefs and values, as well as 
organisational, resource, ethical and policies difference across countries. There has been a 
call for the importance of involving patients, clinicians and other stakeholders - to co-design 
and embed the key features of SCC at local hospital level [66] 
However, while being flexible, the implementation of SCC should also be equitable [24], as 
ethnic and socioeconomic differences in advance care planning and death rate have been 
reported [67] .  
3.1 Ethical counselling  
In order to ‘support’ SCC, we would like to add to the SCC implementation toolkit a 
particular type of ethical counselling (EC) framework developed by Boniolo et al [11]. This EC 
framework has been developed to improve patients’ awareness on the ethical choices they 
may be asked to make whenever clinical options raise ethical dilemmatic situations. It is 
based on two ethical decision-making methodologies, one addressing the patients, the 
other the doctor, and it promotes decisions that are informed and in line with patients’ 
personal philosophies.  The term personal philosophy refers to the “wide set of more or less 
deep, coherent and justified metaphysical, methodological, religious, political, esthetical, 
ethical, etc., beliefs, assumptions, principles, and values that an agent possesses and that 
characterises in a unique way how he/she approaches the world and life. […] The 
‘conceptual and value-laden window’ from which any individual starts reflecting in order to 
make judgments, to make choices, and to act”, [11:p. xiii]. 
This framework is in line with the relational view of autonomy (see sections 2.1, 2.2 and 
[40]), and with research conducted on truth disclosure in oncology [68]. However it has not 
yet been not considered in the SCC literature.  
EC can be an additional tool to help to embed SCC in the cancer trajectory as it is flexible, 
directed at patients and health care providers and it is sustainable. It can also address most 
of the problems related to SCC and the three implementation barriers we have highlighted. 
In particular:   
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 It can help to reduce language and definition confusion around SCC – an important 
role of the EC is clarification of language and to make patients’ and clinicians’ 
potentially misleading assumptions explicit 
 Being a bidirectional reflective tool aimed at both patients and clinicians, EC can help 
clinicians to improve their communication skills, while potentially sharing some of 
the communication task, reducing clinicians’ burnout, and introducing elements of 
training.   
 EC can help both clinicians and patients to address anxiety and fear of death which 
can otherwise hinder adequate understanding of options available and decision 
making- thus reducing clinicians’ burnout and improving patients’ outcomes.  
 EC takes into account cultural and spiritual variations and needs, also in relation to 
how much and how to convey information 
 It is patient centered and aims to improve decision-making by placing emphasis on 
the communication of the relevant information, in a way that is responsive to 
patients’ personal philosophies and needs.   
 It can help patients, professionals and families/ care givers to address conflicts and 
achieve a common therapeutic goal. 
Although oncologists should have a critical coordinative role in providing supportive care, it 
is unrealistic to expect them to address the many dimension of patients’ needs [14] covered 
by SCC.  Moreover, patients have reported that they prefer their oncologists to be optimistic 
about treatment options and to avoid pessimistic discussion about end of life care; 
suggesting that oncologists who focus on cancer treatment and physiological symptom relief 
rather than psychosocial of existential issues may be more desirable [69]. Patients often 
prefer to discuss advance care planning with a clinician who they have never met rather 
than their own clinical oncologist [70]. This is one of the reasons why MDT are crucial. While 
implementing MDT can be a long and resource-intensive process, introducing ethical 
counsellors could help fostering MDT work. They could relieve the ethical/spiritual burden 
on oncologists, and act as gatekeeper between oncologists and other specialities.  
Given the inherent asymmetry of the patient-doctor relationship, it is especially important 
for oncologists to be aware of the difficulties and potential risks of acting as 
ethical/existential or spiritual advisors. This role requires specific education and training that 
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are not yet provided in most medical schools. Yet in most clinical practices worldwide, 
physicians and nurses are often called to address the spiritual concerns of their patients 
(potentially contributing to professional burnout). Spiritual teams are becoming common 
addition to SCC’s MDTs. They generally consist of hospital chaplains or spiritual advisors 
trained to address patient spirituality along with cancer survivors, volunteers, and 
interested oncology professionals [3].  The ethical counsellor may not only contribute to the 
emergence of such ‘spiritual teams’, but –  as they work with both patient and clinicians -  
ethical counsellors can at the same time improve the care received by patient and provide 
support and communication training to the clinician. This makes ethical counselling a very 
valuable (low investment/big gain) resource to organise SCC. 
4. Conclusions  
Alongside biomedical treatments and cure, the ethical /existential dimensions of care are 
very important in cancer – as with many other conditions which can cause suffering. In 
cancer care, the integration of SCC in standard oncology practice is of enormous benefit to 
patients, their families and caregivers, clinicians, and hospitals. Nevertheless, despite these 
benefits - testified also by the efforts of international societies to integrate SCC – SCC is still 
mostly considered as a resource to be used after curative care.  
We have identified three challenges (lack of resources and organisational infrastructures, 
professional burnout, and stigma towards death and dying) which we think should be 
considered in future SCC implementation strategies.  To support SCC, we have also added an 
ethical counselling framework to the SCC implementation toolkit, arguing that the 
framework could offer a sustainable way to embed SCC, addressing the three challenges.  
 As discussed, the implementation of SCC needs to be flexible towards differences in 
organisation, resources, and policies across countries. At the same time it needs to be 
equitable – therefore underpinned by a set of universal principles. As they would work with 
both patients and clinicians (and other stakeholders in hospitals), ethical counsellors could 
help to embed these principles in local contexts, becoming advocate for change.    
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